BHARAT A. SHAH

B.Com. F.C.A. (DISA)

B. A. SHAH ASSOCIATES

Chartered Accountants

209 Sapphire, 2nd Floor, 21/25 - B ,New Jagnath Plot, Rajkot. - 360 001. Ph.: 0281 - 2468261

Auditor's Limited Review Report

On Unaudited Financial Results

То

The Board of Directors, Parmax Pharma Limited

We have reviewed the accompanying statement of unaudited financial results of **PARMAX PHARMA LIMITED** for the quarter ended on **31**st **March 2016**. This statement is the responsibility of the Company's Management.

A review of the interim financial information consist principally of applying analytical procedures for the financial data and making enquiries of persons responsible for financial and 'accounting matters. It is substantially less in scope than audit conducted in accordance with the generally accepted auditing standards, The objective of which is the expression of an opinion . regarding the financial statements taken as a whole. Accordingly we do not express such an opinion. Further our review was mainly in regards to the figures of quarter ended 31st March 2016.

During our review we have noticed that:

There are small differences between amounts as per published results and corresponding figured as per the accounts (which are however within tile allowed limit of 10% or Rs. 10 lacs, whichever is higher)

Except this nothing has come to our notice that causes us to believe that the accompanying statements of unaudited financial results have not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contain any material misstatement.

For B A SHAH ASSOCIATES Chartered Accountants FRN.: 109493W

BHARAT SHAH PROPRIETOR M. NO.034222

Bharit A shall

RAJKOT

Date: 25.04.2016 Place: Rajkot

	ent of Standalone/ Consolidated Unaudited/ Audited Results for Particulars	3 Months ended 31.03.2016	Preceeding 3 months ended 31.12.15	Corresponding 3 months ended 31.03.2015	Year to date figures current period ended 01.04.2015 to 31.03.2016	Previous year ended 2014-15
	(Refer Notes Below	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 1	ncome from Operations					
5		220 -	÷			-
1.0	a) Net sales/income from operation (Net of excise duty) b) Other operating income	600,000.00	-	600,000.00	600,000.00	600,000.0
				600 000 00	600.000.00	600,000.0
Т	otal income from operations (net)	600,000.00	100 J	600,000.00	600,000.00	600,000.0
	xpenses					
14	a) Cost of materials consumed	28	18 10	54 19	(32) 201	
	 b) Purchase of stock-in-trade Changes in inventories of finished goods, work-in-progress and 			-		
	tock-in-trade		a l	×1.	592	
1.122	d) Employee benefits expense	T :		6	222	-
	e) Depreciation and amortisation expense	-	-	2	573	-
	f) Other expenses (Any item exceeding 10% of the total expenses elating to continuing operations to be shown separately)					
		267,888.00	60,632.00	33,433.00	485,690.00	240,282.0
	-	207,000.00	00,002.00	00,100.00		
1	fotal expenses	267,888.00	60,632.00	33,433.00	485,690.00	240,282.0
	Profit/(Loss) from operations before other income, finance costs					
-	and exceptional items (1-2)	332,112.00	(60,632.00)	566,567.00	114,310.00	359,718.0
4 5	other income	*	(*)		/8	
	the first of the second s					
	Profit/ (Loss) from ordinary activities before finance costs and exceptional (3(+ /-)4)	332,112.00	(60,632.00)	566,567.00	114,310.00	359,718.
6 1	Finance costs		3 - 3	×	N	87
7	Profit / (Loss) from ordinary activities after fiance costs but					
	before exceptional items (5(+/-)6)	332,112.00	(60,632.00)	566,567.00	114,310.00	359718
			112			
81	Exceptional items	-	(*			
91	Profit / (Loss) from ordinary activities before tax (7(+/-)8)	332,112.00	(60,632.00)	566,567.00	114,310.00	359,718.
10	Tax expense	*		-		
11					D-HE-DAKE	antiplease
1	Net Profit / (Loss) from ordinary activities after tax (9(+/-)10)	332,112.00	(60,632.00)	566,567.00	114,310.00	359,718.
12	Extraordinary items (net of expense Rs Lakhs)					
13	Net Profit / (Loss) for the period (11(+/-)12)	332,112.00	(60,632.00)	566,567.00	114,310.00	359,718.
14	Share of profit / (Loss) of associates*		5	-		14
15	Minority interest*	1		123	-	
16	Net Profit / (Loss) after taxes, minority interest and share of					
	profit / loss of associates (13(+/-)14(+/-)15)*	332,112.00	(60,632.00)	566,567.00	114,310.00	359,718.
		27 442 000 00	44,545,500.00	40,295,500.00	37,413,000.00	40,295,500
1/	Paid-up equity share capital (Face Value Rs 10)	37,413,000.00	44,545,500.00	40,293,300.00	37,415,000.00	40,200,000
18	Reserve excluding Revaluation Reserves as per balance sheet of			<u>10</u>		941,177.
	previous accounting year	(R)				391.111
	Earnings per share (before extraordinary items)					
	(of Rs/- each) (not annualised):					
- 1	(a) Basic					
	(b) Diluted		1 C			
11	Earnings per share (after extraordinary items)					
	(of Rs/- each) (not annualised):					
	(a) Basic				N	

Select Information for the Quarter End 31.03.2016

Jere	Particulars	3 months ended 31.03.16	Preceding 3 months ended 31.12.15	Corresponding 3 months ended 31.03.15	Year to date figures for current period ended 01-04-15 to 31- 03-16	Previous year ended 2014-15
	PARTICULARS OF SHAREHOLDING					
1	1 Public shareholding	S. Doctored	W. C. C. C. C. C. C.			4010050
	Number of shares	2650550	4010050	4010050	2650550	4010050
-	Percentage of shareholding	70.85%	78.62%	78.62%	70.85%	78.62%
	2 Promoters and Promoter Group Shareholding **	3.				
	a) Pledged / Encumbered	Nil	Nil	Nil	Nil	Nil
	Number of shares	20011				
	Percentage of shares (as a % of the total shareholding					
	of promoter and promoter group	Nil	Nil	Nil	Nil	Nil
	Percentage of shares (as a % of the total share capital					
	of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non-entrumbered					
	Percentage of shares (as a % of the total shareholding					
	of promoter and promoter group	29.15%	21.38%	21.38%	29.15%	21.38%
	Percentage of shares (as a % of the total share capital				11000000000	
	of the company)	100%	100%	100%	100%	100%

	Particulars	3 months ended (dd/mm/yyyy
В	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Ramaining unresolved at the end of the quarter	Nil

Note:

The above results were reviewed by an Audit Committee and thereafter taken on record by the Board of Directors in their meeting held on 30.05.2016

There were no investor complaints known to the Company outstanding at the beginning of the quarter.

Previous period figures have been regrouped wherever necessary.

Any other notes to be added.

Clause 41 of the Listing Agreement For companies (Other than Banks)

	Stadalone / Consolidated Statement of Assets and Liabilities Particulars	As at 31-03-2016	As at 31-03-2015
Ą	EQUITY AND LIABILITIES		
1	Shareholder's funds		
	(a) Share capital	44511500	40295500
	(b) Reserves and surplus	1,263,020	1,165,894
	© Money received against share warants	0	C
	Sub- total - Shareholder's funds	45774520	41,461,394
	Share application money pending		
2	allotment	0	C C
	Minority interest*	0	
4	Non-current liabilities		
	(a) Long-term borrowings	4649177	7899176
	(b) Deferred tax liabilities (net)	0	(
	© Other long-term liabilities	C	(
	(d) Long-term provisions	C	
	Sub-total-Non-current liabilities	4649177	789917
	Current liabilities		
	(a) Short-term borrowings	C	
	(b) Trade payables	86249	6623
	(c) Other current liabilities	34000	
	(d) Short-term provisions	185900	31500
	Sub-total- Current liabilities	306149	38123
	TOTAL - EQUITY AND LIABILITIES	50729846	4974180
В	ASSETS		
	1 Non-current assets		
	(a) Fixed assets	25331120	2533112
	(b) Goodwill on consolidation*	(
	(c) Non-current investments	6000	600
	(d) Deferred tax assets (net)	()
	(e) Long-term loans and advances	734400	73440
	(f) Other non-current assets	8524466	852446
	Sub-total-Non-current assets	34595986	3459598
	2 Current assets		
	(a) Current investments		0
	(b) Inventories		
	© Trade receivables	937360	82415
	(d) Cash and cash equivalents	306666	3 214969
	(e) Short-term loans and advances	1212983	7 1217196
	(f) Other current assets		C
	Sub-total-Current assets	1613386	1514581
	TOTAL - ASSETS	5072984	6 4974180